Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 20-98 / BIG 2-98 

A phase III trial to evaluate the activity of docetaxtel given either sequentially or in combination with doxorubicin, followed by CMF, in comparison to doxorubicin alone or in combination with cyclophosphamide, followed by CMF, in the adjuvant treatment of node-positive breast cancer patients

DESIGN

Design Trial 20-98

Results & Publications


Presentations


Publications

Study Chairs
BIG: Dr. Martine Piccart - Brussels, Belgium
IBCSG: Dr. Prue Francis - Melbourne, Australia
SAKK: Dr. Lucien Perey - Lausanne, Switzerland
SAKK: Dr. Dagmar Hess - St. Gallen, Switzerland

Trial Monitor
Giuseppe Achille
IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: giuseppe.achille@ibcsg.org

Date of Activation
June 1998

Date of Closure
June 26, 2001

Targeted Accrual
2730 patients

Final Accrual
2890 patients


Results Publications Results & Publications
Other Pathology


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print